Published in AIDS Weekly, February 24th, 1997
So far, the approach appears safe, and early efficacy data suggest that it might be working.
J. Oleske and colleagues at the University of Medicine and Dentistry of New Jersey, Newark, created a vaccine comprised of blood cells, plasma, and cell-free virus bound to a potent adjuvant. The individually tailored vaccine is intended to stimulate new and existing anti-HIV immune responses.
Oleske et al. reported their study at the Fourth Conference on Retroviruses and Opportunistic Infections, held January 22-26, 1997, in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.